SEARCH

SEARCH BY CITATION

References

  • 1
    Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 21082131.
  • 2
    Bommelaer G, Poynard T, Le Pen C, et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol Clin Biol 2004; 28: 554561.
  • 3
    De Giorgio R, Barbara G, Stanghellini V, et al. Diagnosis and therapy of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20(Suppl. 2): 1022.
  • 4
    Gwee KA, Chua AS. Functional dyspepsia and irritable bowel syndrome, are they different entities and does it matter? World J Gastroenterol 2006; 12: 27082712.
  • 5
    Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective. Aliment Pharmacol Ther 2006; 24: 183205.
  • 6
    Quigley EM. The use of probiotics in functional bowel disease. Gastroenterol Clin North Am 2005; 34: 533545.
  • 7
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): II43I7.
  • 8
    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 14801491.
  • 9
    Azpiroz F, Malagelada JR. Abdominal bloating. Gastroenterology 2005; 129: 10601078.
  • 10
    Amouretti M, Le Pen C, Gaudin AF, et al. Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). Gastroenterol Clin Biol 2006; 30: 241246.
  • 11
    Ten Berg MJ, Goettsch WG, Van Den BG, Smout AJ, Herings RM. Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. Eur J Gastroenterol Hepatol 2006; 18: 475481.
  • 12
    Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654660.
  • 13
    Inadomi JM, Fennerty MB, Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 671682.
  • 14
    Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 12311238.
    Direct Link:
  • 15
    Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 687696.
  • 16
    O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541551.
  • 17
    Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 15811590.
    Direct Link:
  • 18
    Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome–a double blind, placebo-controlled, randomized study. Clin Nutr 2005; 24: 925931.
  • 19
    Camilleri M. Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 2006; 40: 264269.
  • 20
    Floch MH. Use of diet and probiotic therapy in the irritable bowel syndrome: analysis of the literature. J Clin Gastroenterol 2005; 39: S243S246.
  • 21
    Young P, Cash BD. Probiotic use in irritable bowel syndrome. Curr Gastroenterol Rep 2006; 8: 321326.
  • 22
    Méance S, Cayuela C, Turchet P, Raimondi A, Lucas C, Antoine JM. A fermented milk with a Bifidobacterium probiotic strain DN-173 010 shortened oro-fecal gut transit time in elderly. Microb Ecol Health Dis 2001; 13: 217222.
  • 23
    Méance S, Cayuela C, Turchet P, Raimondi A, Lucas C, Antoine JM. Recent advances in the use of functional foods: effects of the commercial fermented milk with Bifidobacterium animalis strain DN-173 010 and yoghurt strains on gut transit time in the elderly. Microb Ecol Health Dis 2003; 15: 1522.
  • 24
    Marteau P, Cuillerier E, Méance S, et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: A double blind randomised controlled study. Aliment Pharmacol Ther 2002; 16: 587593.
  • 25
    Bouvier M, Méance S, Bouley C, Berta JL, Grimaud JC. Effects of consumption of a milk fermented by a probiotic Bifidobacterium animalis (strain DN-173 010) on colonic transit times in healthy humans. Biosci Microflora 2001; 20: 4348.
  • 26
    Berrada N, Lemeland JF, Laroche G, Thouvenot P, Piaia M. Bifidobacterium from fermented milks: Survival during gastric transit. J Dairy Sci 1991; 74: 409413.
  • 27
    Pochart P, Marteau P, Bouhnik Y, Goderel I, Bourlioux P, Rambaud JC. Survival of Bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion. Am J Clin Nutr 1992; 55: 7880.
  • 28
    Duez H, Pelletier C, Cools S, et al. A colony-immunobloting method for quantitative detection of a Bifidobacterium animalis probiotic strain in human faeces. J Appl Microbiol 2000; 88: 10191027.
  • 29
    Chassany O, Marquis P, Scherrer B, et al. Validation of a specific quality of life questionnaire for functional digestive disorders. Gut 1999; 44: 527533.
  • 30
    FDA Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labelling claims. 2006. http://www.fda.gov/cder/guidance/5460dft.pdf
  • 31
    European Agency for the Evaluation of Medicinal Products (EMEA). Committee for proprietary medicinal products (CPMP). Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. CPMP/EWP/785/97, 2006. http://www.emea.eu.int/pdfs/human/ewp/078597en.pdf
  • 32
    Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47: 8187.
  • 33
    Sloan JA, Frost MH, Berzon R, et al. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer 2006; 14: 988998.
  • 34
    Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920924.
  • 35
    Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27(Suppl. 3): S178S189.
  • 36
    Lagakos SW. The challenge of subgroup analyses : reporting without distorting. N Engl J Med 2006; 354: 16671669.
  • 37
    Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, et al. Design of treatment trials for the functional gastrointestinal disorders. In: DrossmanDA, CorazziariE, TalleyNJ, et al. , eds. Rome II. Functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment : a multinational consensus. Degnon Associates, Mc Lean: VA, USA, 2000: 577622.
  • 38
    Irvine EJ, Withehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006; 130: 15381551.
  • 39
    Corazziari E, Bytzer P, Delvaux M, et al. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 569580.
  • 40
    Marquis P, Chassany O, Abetz L. A comprehensive strategy for the interpretation of quality of life data based on existing methods. Value Health 2004; 7: 93104.
  • 41
    Schunemann HJ, Akl EA, Guyatt GH. Interpreting the results of patient reported outcome measures in clinical trials: the clinician’s perspective. Health Qual Life Outcomes 2006; 4: 62.
  • 42
    Yalcin I, Patrick DL, Summers K, Kinchen K, Bump RC. Minimal clinically important differences in Incontinence Quality-of-Life scores in stress urinary incontinence. Urology 2006; 67: 13041308.
  • 43
    Watson ME, Lacey L, Kong S, et al. Alosetron improves quality of life in women with diarrhoea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 455459.
    Direct Link:
  • 44
    Withehead WE, Palsson OS, Levy RL, Feld AD, VonKorff M, Turner M. Reports of “satisfactory relief” by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol 2006; 101: 10571065.
    Direct Link:
  • 45
    Enck P, Klosterhalfen S. The placebo response in functional bowel disorders: perspectives and putative mechanisms. Neurogastroenterol Motil 2005; 17: 325331.
  • 46
    Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 237247.
  • 47
    Veldhuyzen van Zanten SJO, Armstrong D, Chiba N, et al. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled “ENTER” trial. Am J Gastroenterol 2006; 101: 20962106.
    Direct Link:
  • 48
    Su C, Lichtenstein GR, Krok K, Brensiger CM, Lewis JD. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn’s disease. Gastroenterology 2004; 126: 12571269.
  • 49
    Conboy LA, Wasserman RH, Jacobson EE, et al. Investigating placebo effects in irritable bowel syndrome: a novel research design. Contemp Clin Trials 2006; 27: 123134.
  • 50
    Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME. Treatment of irritable bowel syndrome with Lacteol Fort®: a randomized, double-blind, cross-over trial. Am J Gastroenterol 1996; 91: 15791585.
  • 51
    Verdù EF, Bercick P, Bergonzelli GE, et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 2004; 127: 826837.
  • 52
    Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, De Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005; 2: CD003460.
  • 53
    Lembo T, Naliboff B, Munakata J, et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol 1999; 94: 13201326.
    Direct Link:
  • 54
    Quigley EM. From comic relief to real understanding; how intestinal gas causes symptoms. Gut 2003; 52: 16591661.
  • 55
    Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 895904.
  • 56
    King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352: 11871189.
  • 57
    Dear KL, Elia M, Hunter JO. Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome? Dig Dis Sci 2005; 50: 758766.
  • 58
    Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 412419.
  • 59
    Harder H, Serra J, Azpiroz F, Passos MC, Aguade S, Malagelada JR. Intestinal gas distribution determines abdominal symptoms. Gut 2003; 52: 17081713.
  • 60
    Serra J, Azpiroz Fand Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001; 48: 1419.
  • 61
    Serra J, Azpiroz F, Malagelada JR. Mechanisms of intestinal gas retention in humans: impaired propulsion vs. obstructed evacuation. Am J Physiol Gastrointest Liver Physiol 2001; 281: G138G143.
  • 62
    Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101: 326333.
    Direct Link:
  • 63
    Quigley EM. Germs, gas and the gut; the evolving role of the enteric flora in IBS. Am J Gastroenterol 2006; 101: 334335.
    Direct Link:
  • 64
    Koebnick C, Wagner I, Leitzmann P, Stern U, Zunft HJ. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 2003; 17: 655659.